Avenacy intros 5 generics
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, is offering a new suite of antibiotic products for injection, including:
- Ampicillin for injection, which is a generic for Bayer AG’s Omnipen-N.
- Ampicillin and dulbactam for injection, which is a generic of Pfizer’s Unasyn.
- Nafcillin for injection, which is a generic of Baxter Healthcare’s Nallpen.
- Penicillin G potassium for injection, which is a generic of Pfizer’s Pfizerpen.
- Piperacillin and tazobactam for injection, which is a generic of Baxter Healthcare’s Zosyn.
[Read more: Avenacy intros generic Reglan]
Avenacy noted that combined, these products generated U.S. sales of approximately $175 million for the 12 months ended Sept. 30, 2024, per IQVIA.
“The launch of these five antibiotic products further strengthens Avenacy’s foundational portfolio of high-usage, critical injectable products. I am proud of how swiftly this team has worked to successfully bring 20 important medications to the U.S. market,” said Jeff Yordon, co-founder and CEO of Avenacy.
[Read more: Generic sterile injectables market to reach $196.2B by 2029]
Yordon continued, “As we continue to focus on accelerating our growth, these antibiotic products will enable us to deepen our commercial presence in both the hospital and long-term/home health settings. With our growing antibiotic portfolio, we are well-positioned to drive continued market expansion that supports our long-term strategic objectives.”
The company said that all five antibiotic products will feature the company’s highly differentiated packaging and labeling to support accurate medication selection.
